[Injection of PRP (Platelet-rich plasma) as a treatment for androgenetic alopecia : a systematic review of the literature]. / Injection de PRP (Plasma riche en plaquettes) comme traitement de l'alopécie androgénétique : une revue systématique de la littérature.

INTRODUCTION: Androgenetic alopecia is the most frequent alopecia both in men and women. Despite it affects a large proportion of the population, they are few therapeutic options often restrictive. The injection of PRP in alopecic areas is a new and easy therapeutic option. The aim of this article is to systematically review the literature about this topic by analysing the articles describing the clinical results of this new technique in the treatment of androgenetic alopecia in men and / or women with a follow-up of minimum 6 months. MATERIAL AND METHODS: A systematic review of the PRISMA type from several databases was carried out and identified 7 articles meeting the following inclusion criteria: 1) articles describing the clinical results of the injection of PRP for the treatment of androgenetic alopecia, 2 ) in men and / or women, 3) written in English or French, 4) with clinical follow-up of at least 6 months, and 5) with objective criteria for follow-up of patients and observed complications. These prospective clinical studies are analyzed and compared qualitatively. CONCLUSION: This systematic review of the literature resulted in a qualitative analysis of 7 scientific studies on the effect of PRP injection as a treatment for androgenetic alopecia. Although all the studies concluded in a favorable effect of this new treatment, a larger, rigorous study with objective analysis of the therapeutic effect is necessary.

INTRODUCTION: L'alopécie androgénétique est l'alopécie la plus fréquente que ce soit chez l'homme ou la femme. Bien qu'elle touche une grande partie de la population, les options thérapeutiques sont peu nombreuses et souvent contraignantes. L'injection de PRP dans les zones alopéciques est une nouvelle possibilité de traitement plus simple. Cet article a pour objectif de réaliser une revue systématique sur le sujet en analysant les articles décrivant les résultats cliniques de cette nouvelle technique dans le traitement de l'alopécie androgénétique, chez l'homme et/ou la femme, comprenant un followup de minimum 6 mois. Matériel et méthodes : Une revue systématique de type PRISMA au départ de plusieurs banques de données a été réalisée et a identifié 7 articles remplissant les critères d'inclusion suivants : (1) articles décrivant les résultats cliniques de l'injection de PRP pour le traitement de l'alopécie androgénétique, (2) chez l'homme et/ou la femme, (3) écrits en anglais ou en français, (4) avec un suivi clinique de minimum 6 mois, (5) avec description de critères objectifs pour le suivi des patients et des complications observées. Ces études cliniques prospectives sont analysées et comparées qualitativement. CONCLUSION: Cette revue systématique de la littérature a permis de réaliser une analyse qualitative de 7 études scientifiques sur l'effet de l'injection du PRP comme traitement de l'alopécie androgénétique. Bien que l'ensemble des études analysées soit en faveur d'un effet favorable de ce nouveau traitement, une étude de plus grande ampleur, rigoureuse avec analyse objective de l'effet thérapeutique est nécessaire.

Fatal hyperammonemia after renal transplant due to late-onset urea cycle deficiency: a case report.

We present a case of severe hyperammonemia with subsequent brain herniation in an adult man after renal transplantation. After successful surgery and an initially uneventful postoperative course, the patient developed significant mental status changes associated with seizure activity. His condition rapidly deteriorated, requiring mechanical ventilation and cardiovascular support. Laboratory studies at that time demonstrated an increased serum ammonia level without evidence of liver or kidney dysfunction. Further investigation revealed an increased orotic acid level in the urine, suggesting a urea cycle disorder (UCD). Despite aggressive therapy, the patient's condition continued to deteriorate. Magnetic resonance imaging demonstrated severe brain edema with no cerebral perfusion; after consultation with the family, care was withdrawn. The combination of hyperammonemia and elevated urine orotic acid with normal liver and kidney function suggested a UCD. It is important to note that patients with a UCD may be free of symptoms for many years. Several factors are able to trigger the disease in adulthood, leading to encephalopathy and death. In this case, the patient's seizures were initially assumed to be a side effect of immunosuppressive therapy. Further diagnostic measures were only performed late in the course of the disease, which delayed the diagnosis of UCD.

Trichothiodystrophy-like hair abnormalities in a child with keratitis ichthyosis deafness syndrome.

Keratitis ichthyosis deafness syndrome is a rare congenital ectodermal disorder. It appears to be genetically heterogeneous and may be caused by mutations in the connexin 26 (Cx26) gene (GJB2) or in the connexin 30 gene. It is characterized by the association of ichthyosis-like skin lesions, hearing loss, and vascularizing keratitis. We report the clinical and molecular findings in a 5-year-old girl with keratitis ichthyosis deafness syndrome. DNA sequencing in our patient revealed a p.Ser17Phe mutation in GJB2. Besides the typical clinical features of keratitis ichthyosis deafness syndrome, a peculiar intriguing finding not previously described in the literature in this condition was that polarizing light microscopy of the scalp hair in our patient revealed striking bright and dark bands as seen in trichothiodystrophy. Amino acid analysis of the hair sample also disclosed a reduced cysteine index. We emphasize that it would be of great benefit to examine hair shafts in other patients with keratitis ichthyosis deafness syndrome for trichothiodystrophy-like abnormalities.

Earlier occurrence of severe alopecia areata in HLA-DRB1*11-positive patients.

BACKGROUND: Alopecia areata (AA) is a polygenic immune-mediated disorder affecting the hair follicle for which an association with human leukocyte antigen HLA-DRB1*11 has been described. OBJECTIVE: Two parameters including age of onset and extent of the disease (patchy AA and AT/AU forms) were correlated with the presence or absence of HLA-DRB1*11 and its alleles in 88 severe AA patients. METHODS: Patients and healthy controls were typed for HLA-DR and -DQ by molecular method. RESULTS: Among AA patients, 37.5% (a proportion rising to 72% when taking patients who began their first patch before the age of 20 years) were positive for HLA-DRB1*11 compared to 21.2% healthy controls (p = 0.004, RR = 2.1). DRB1*11-positive status was associated with earlier development of the first AA patch, at the mean age of 16 years compared to 27 years (p = 0.003) in DRB1*11-negative patients. Among the DRB1*11 alleles, the presence of DRB1*1104 was associated with the earliest occurrence of AA. CONCLUSION: Our data indicate that the HLA system largely through DRB1*1104 allele influences AA onset rather than extension considering patchy AA and AT/AU.

[Hair physiology]. / La physiologie du cheveu.

The first hair follicles appear on the body toward the end of the 8th week of intrauterine life. The appearance on the scalp is more tardive 7th month. The hair is a keratin-containing appendage that grows from cavities called follicles. Hair follicles extend from the surface of the skin through the stratum corneum and the epidermis into the dermis. Keratin contains almost all aminoacids but particularly rich in cystein. Hair fibers grow in three distinct stages. The first one, the anagen stage, is the growing phase with a duration of 3 to 5 years. The catagen stage, the transition stage, lasts only a few weeks; it precedes the telogen stage, resting or shedding phase, lasts for 2 months.

[Alopecia areata and treatment]. / La pelade et son traitement.

Alopecia areata is a non scarring inflammatory hair disease, frequently recurrent. It commonly presents as round patches of hair loss which can be the first manifestation of a more severe alopecia: totalis or universalis. A CD4 lymphocytic infiltrate surrounds the hair follicle and is presumed to play a role in the hair fall. There are many treatments available which may help stimulate regrowth. The efficacy, risks, and benefits of each treatment have to be considered when choosing a treatment plan.

Finasteride increases anagen hair in men with androgenetic alopecia.

BACKGROUND: The growth of scalp hair is a cyclical process of successive phases of growth (anagen) and rest (telogen). In previous clinical trials in men with androgenetic alopecia, treatment with finasteride increased scalp hair counts in a defined area (i.e. increased hair density). OBJECTIVES: The current study used a phototrichogram methodology to assess the effect of finasteride on the phases of the hair growth cycle. PATIENTS/METHODS: Two hundred and twelve men, age 18-40 years, with androgenetic alopecia were randomized to receive finasteride 1 mg daily or placebo for 48 weeks. At baseline and at 24 and 48 weeks, macrophotographs were taken to measure total and anagen hair count in a 1-cm(2) target area of the scalp. RESULTS: At baseline, mean total and anagen hair counts in the finasteride group were 200 and 124 hairs, respectively (% anagen = 62%) and the anagen to telogen ratio was 1.74 (geometric mean). In the placebo group, the respective values were 196 and 119 hairs (% anagen = 60%) and 1.57. At week 48, the finasteride group had a net improvement (mean +/- SE) compared with placebo in total and anagen hair counts of 17.3 +/- 2.5 hairs (8.3% +/- 1.4%) and 27.0 +/- 2.9 hairs (26% +/- 3.1%), respectively (P < 0.001). Furthermore, treatment with finasteride resulted in a net improvement in the anagen to telogen ratio of 47% (P < 0.001). In this study, treatment with finasteride 1 mg day(-1) for 48 weeks increased both total and anagen hair counts, and improved the anagen to telogen ratio. CONCLUSIONS: These data provide direct evidence that finasteride 1 mg daily promotes the conversion of hairs into the anagen phase. These data support that finasteride treatment results in favourable effects on hair quality that contribute to the visible improvements in hair growth observed in treated patients.

Further evidence for autosomal dominant inheritance and ectodermal abnormalities in Kabuki syndrome.

Most cases with Kabuki syndrome (KS) were reported sporadically. Recently, a few familial cases of KS were reported. This report provides further evidence that the KS is inherited as a dominant trait with variable expressivity. The proposita is an 18-month-old girl with facial findings characteristic of Kabuki syndrome, prominent fingertip-pads, a midsagittal cleft of vertebral body D4, hypotonia, and psychomotor retardation. Her mother had a similar facial appearance, prominent, cup-shaped ears, an abnormal dentition, early breast development, and low-normal intelligence. Because mother and daughter both had evident Kabuki syndrome, we conclude that KS in this family is inherited as a dominant trait. Further family history supports this finding. Microscopic examination of the hair of the proposita shows abnormalities consisting of trichorrhexis nodosa, twisting of the hairshafts, and irregularity of the diameter of the hair, as was described recently in a patient with KS. This could be another occasional finding in this syndrome, but further studies are required. The presence of abnormal hair, nails, and the commonly described tooth abnormalities in KS further suggest ectodermal involvement in this syndrome.

Pulse steroid therapy for children's severe alopecia areata?

Seven children with severe, rapidly evolving alopecia areata (AA) were treated with pulse steroid therapy (PST). AA had been present for 3-44 weeks and involved more than 30% of the scalp. One patient had alopecia totalis. Intravenous methylprednisolone (5 mg/kg twice a day) was administered for 3 days. No serious side effects were noted. At the 12-month follow-up, complete regrowth had occurred in 5 patients (71%). The patient with alopecia totalis had no regrowth. PST appears to be a promising and safe treatment for extensive, recent-onset AA in children. No response is to be expected in alopecia totalis or long-standing AA.

Netherton's syndrome: a severe neonatal disease. A case report.

A male infant was born with generalized erythroderma and scaling; the newborn demonstrated poor neonatal development and developed several complications such as hypernatremic dehydration, septicemia, gastroenteritis and seizures. In the neonatal period, the erythema faded, but exfoliation persisted. The parents are healthy but related. One older brother, who died at the age of 3 months, had shown the same clinical picture in the neonatal period and was diagnosed with congenital psoriasis. All clinical investigations, including serum immunoglobulins, complement levels and lymphocyte counts, were normal. Only raised total IgE and multiple positive specific IgE reactions were noted. Skin biopsy revealed an image of ichthyosis. Polarization microscopy of scalp hair showed trichorrhexis nodosa and discrete focal twisting of the hair shaft. This clinical picture and all histological findings are compatible with the indications of Netherton's syndrome. The purpose of this report is to call attention to this severe presentation of congenital ichthyosis in the neonatal period and to the difficulty of a correct diagnosis when confronted with congenital erythroderma.

Use of a Beck Airway Airflow Monitor and controllable-tip endotracheal tube in two cases of nonlaryngoscopic oral intubation.

Alternative techniques and equipment for intubation may be particularly useful in settings such as air-medical transport, prehospital on-scene care, mass casualty incidents, or incidents in which there may be a lack of medications or equipment. Once traditional techniques of endotracheal intubation and tube verification have been mastered, emergency medicine residents and other intubators should be encouraged to learn alternative techniques, such as these, that may be of use in some special situations, even within the ED. Neither of these two techniques of BAAM-assisted blind oral intubation can be considered essential, nor should it be contended that these techniques supplant learning of more conventional methods of endotracheal intubation and tube placement verification. However, particularly in the setting of residency training, multiple methods of endotracheal intubation should be taught in order to allow the clinician alternative methods if unable to intubate by traditional means in a particular setting. Use of a BAAM to assist in blind oral intubation of a spontaneously breathing patient may allow for oral intubation of awake patients without the additional use of paralytic medications. Use of the BAAM with a digital technique during external cardiac massage may facilitate intubation by the digital technique and help to verify endotracheal tube position. These two additional uses for the BAAM should be noted and these two additional methods of airway control be recognized as backup methodologies in the armamentarium for situations in which they may be needed.

Small intrapulmonary artery lung prototypes: design, construction, and in vitro water testing.

Blind-ended, hollow fibers mounted on a pulmonary artery catheter may allow O2 and CO2 transfer in the vena cava, right ventricle, and pulmonary artery. The effects of fiber length, manifold number, and gas oscillation on mass and momentum transfer with water perfusate using mass spectrometry and mass flow controllers were studied. Manifolds with 112-196 microporous polypropylene fibers were mounted on 8 Fr multiple lumen, commercially available pulmonary artery catheters. Fiber lengths varied from 0.5 to 16 cm and surface areas from 7 to 220 cm2. Prototypes with 2 cm long fibers were constructed with 1-15 manifolds. A two manifold prototype with 8 cm long fibers and a surface area of 378 cm2 was also studied. The transfer failed to scale with manifold number because the steady gas flow was maldistributed to the manifolds. Oscillating gas pressures from 780 to 76 mmHg absolute at a rate of 40 cycles/min increased CO2 transfer up to 15-fold and O2 transfer up to 2.5-fold. Oscillation also corrected the maldistribution. Optimal fiber lengths of 3 and 1 cm for O2 and CO2, respectively, were seen with steady gas flow, and 8 cm for both with oscillatory gas flow.

The BAAM and endotrol endotracheal tube for blind oral intubation. Beck Airway Air Flow Monitor.

Blind oral intubation in a spontaneously breathing patient can be facilitated with a combination of two devices used mainly for nasotracheal intubation, the BAAM (Beck Airway Air Flow Monitor, Great Plains Ballistics, Lubbock, TX) and the Endotrol endotracheal tube (Mallinckrodt Critical Care, Inc., St. Louis, MO). We describe a case in which intubation of a spontaneously breathing intensive care unit patient was unsuccessful by traditional methods. In the successful approach we describe, the tube was passed through the oral cavity and pharynx in a blind fashion, using the BAAM's whistling sound for guidance and the plastic ring of the Endotrol tube to help positioning. This equipment combination may be useful in certain difficult intubation situations.

Clinical trials of an intravenous oxygenator in patients with adult respiratory distress syndrome.

In patients with severe adult respiratory distress syndrome, mechanical ventilation may not be able to ensure gas exchange sufficient to sustain life. We report the use of an intravenous oxygenator (IVOX) in five patients who were suffering from severe adult respiratory distress syndrome as a result of aspiration, fat embolism, or pneumonia. IVOX was used in an attempt to provide supplemental transfer of CO2 and O2 and thereby reduce O2 toxicity and barotrauma. All patients were tracheally intubated, sedated, and chemically paralyzed and had a PaO2 < 60 mmHg when the lungs were ventilated with an FIO2 = 1.0 and a positive end expiratory pressure of > or = 5 cmH2O. The right common femoral vein was located surgically, and the patient was systemically anticoagulated with heparin. A hollow introducer tube was inserted into the right common femoral vein, and the furled IVOX was passed into the inferior vena cava and advanced until the tip was in the lower portion of the superior vena cava. IVOX use ranged from 2 h to 4 days. In this group of patients, IVOX gas exchange ranged from 21 to 87 ml x min-1 of CO2 and from 28 to 85 ml x min-1 of O2. One of the five patients survived and was discharged from the hospital. The IVOX transferred up to 28% of metabolic gas-exchange requirements. One patient with a small vena cava showed signs of caval obstruction. Three other patients demonstrated signs of a septic syndrome after the device was inserted.(ABSTRACT TRUNCATED AT 250 WORDS)

Experiences with risk estimates for carriers of chromosomal reciprocal translocations.

The risk estimates for individual carriers of ten different familial reciprocal translocations detected among 500 couples with reproductive failures are presented. These were established by application of the empirical data analysed by Stengel-Rutkowski et al. (1988) and the guidelines given in Stene & Stengel-Rutkowski (1988). Different risks were estimated for unbalanced offspring at birth or at second trimester prenatal diagnosis for abortions, or stillbirths/early deaths. These risk estimates varied considerably from translocation to translocation. Carriers of five translocations had risks for offspring with single-segment imbalances. The birth risk figures ranged from 0.1% to 13.8%. Carriers of five other translocations had risks for double-segment imbalances with birth risks ranging from 0% to 3.2%. The estimated risk figures were independent of the method of ascertainment. Among the parents of the index cases we found nine maternal carriers and only one paternal carrier. This presentation illustrates the need for individual risk counselling of each carrier with reciprocal translocation regarding further family planning.

Trauma anesthesia and critical care: the concept and rationale for a new subspecialty.

Proper care of the severely injured patient will require the development of a new anesthesia specialist. The trauma anesthesiologist, like the cardiovascular anesthesiologist, must become thoroughly familiar with one disease. The anesthesiologist who manages patients with traumatic disease must become an expert in critical care, high-risk anesthesia practice, and emergency resuscitation of the trauma patient. An outline for a fellowship in trauma anesthesia and critical care is included.

Renal failure in the trauma patient.

Acute renal failure is a serious complication of the resuscitation and post-traumatic critical care of the severely injured patient. Renal ischemia secondary to shock is the most common cause of post-traumatic renal failure. The unrecognized or untreated renal ischemic state can lead to nephrotoxic damage in the post-traumatic patient. Prevention of acute failure by rapid resuscitation and restoration of circulating volume to prevent ongoing renal ischemia and prerenal azotemia is imperative for reducing the incidence of post-traumatic renal failure. Once post-traumatic renal failure is established, aggressive dialysis can reduce the mortality resulting from post-traumatic renal failure.